Invention Grant
- Patent Title: Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof
-
Application No.: US18573904Application Date: 2022-06-24
-
Publication No.: US12161722B2Publication Date: 2024-12-10
- Inventor: Pil Ho Kim , Sung Yun Cho , Jae Du Ha , Chi Hoon Park , Jong Yeon Hwang , Hyun Jin Kim , Song Hee Lee , Ye Seul Lim , Han Wool Kim , Sun Mi Yoo , Beom Seon Suh , Ji Youn Park , Je Ho Ryu , Jung Min Ahn , Hee Jung Moon , Ho Hyun Lee
- Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , UBIX THERAPEUTICS, INC.
- Applicant Address: KR Daejeon; KR Seoul
- Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,UBIX THERAPEUTICS, INC.
- Current Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,UBIX THERAPEUTICS, INC.
- Current Assignee Address: KR Daejeon; KR Seoul
- Agency: ROTHWELL, FIGG, ERNST & MANBECK, P.C.
- Priority: KR10-2021-0083326 20210625,KR10-2022-0077174 20220623
- International Application: PCT/KR2022/009087 WO 20220624
- International Announcement: WO2022/270994 WO 20221229
- Main IPC: A61K47/55
- IPC: A61K47/55 ; A61K47/54 ; A61K47/60
Abstract:
The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
Public/Granted literature
Information query
IPC分类:
